Abstract
Purpose
Traditional Chinese medicine is one of the popular alternative treatments for cancer, mainly enhancing host immune response and reducing adverse effect of chemotherapy. This study first explored traditional Chinese medicine treatment effect on long-term survival of lung cancer patients.
Methods
This study evaluated whether traditional Chinese medicine combined with conventional cancer treatment improved overall survival of lung cancer patients. We had conducted a retrospective cohort study on 111,564 newly diagnosed lung cancer patients in 2000–2009 from National Health Insurance Program database.
Results
A total of 23,803 (21.31%) patients used traditional Chinese medicine for lung cancer care. Eligible participants were followed up until 2011 with a mean follow-up period of 1.96 years (standard deviation 2.55) for non-TCM users and 3.04 years (2.85) for traditional Chinese medicine users. Patients with traditional Chinese medicine utilization were significantly more likely to have a 32% decreased risk of death [hazard ratio = 0.62; 95% confidence interval = 0.61–0.63], compared with patients without traditional Chinese medicine utilization after multivariate adjustment. We also observed a similar significant reduction risk across various subgroups of chronic lung diseases. Qing Zao Jiu Fei Tang was the most effective traditional Chinese medicine agent for mortality reduction both in the entire lung cancer (0.81; 0.72–0.91) and matched populations (0.86; 0.78–0.95).
Conclusion
This study demonstrated adjunctive therapy with traditional Chinese medicine may improve overall survival of lung cancer patients. This study also suggested traditional Chinese medicine may be used as an adjunctive therapy for cancer treatment. These observational findings need being validated by future randomized controlled trials to rule out the possibility of effect due to holistic care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
ALA (2015) Complementary and alternative therapies. www.mylungcancersupport.org/treating-lung-cancer/complementary.html Accessed March 2015
Chang LC, Huang N, Chou YJ, Lee CH, Kao FY, Huang YT (2008) Utilization patterns of Chinese medicine and Western medicine under the National Health Insurance Program in Taiwan, a population-based study from 1997 to 2003. BMC Health Serv Res 8:170. doi:10.1186/1472-6963-8-170
Chao TH, Fu PK, Chang CH, Chang SN, Chiahung Mao F, Lin CH (2014) Prescription patterns of Chinese herbal products for post-surgery colon cancer patients in Taiwan. J Ethnopharmacol 155:702–708. doi:10.1016/j.jep.2014.06.012
Chen FP, Chen TJ, Kung YY, Chen YC, Chou LF, Chen FJ, Hwang SJ (2007) Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res 7:26. doi:10.1186/1472-6963-7-26
Chen FP, Kung YY, Chen YC, Jong MS, Chen TJ, Chen FJ, Hwang SJ (2008) Frequency and pattern of Chinese herbal medicine prescriptions for chronic hepatitis in Taiwan. J Ethnopharmacol 117:84–91. doi:10.1016/j.jep.2008.01.018
Chen S, Flower A, Ritchie A, Liu J, Molassiotis A, Yu H, Lewith G (2010) Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review. Lung Cancer 68:137–145. doi:10.1016/j.lungcan.2009.11.008
Chi C, Lee JL, Lai JS, Chen CY, Chang SK, Chen SC (1996) The practice of Chinese medicine in Taiwan. Soc Sci Med 43:1329–1348
Chi C, Lee JL, Lai JS, Chen SC, Chen CY, Chang SK (1997) Utilization of Chinese medicine in Taiwan. Altern Ther Health Med 3:40–53
Chou P (2001) Factors related to utilization of traditional Chinese medicine in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 64:191–202
Chung V, Wong E, Woo J, Lo SV, Griffiths S (2007) Use of traditional chinese medicine in the Hong Kong special administrative region of China. J Altern Complement Med 13:361–367. doi:10.1089/acm.2006.6152
Chung V, Lau CH, Yeoh EK, Griffiths SM (2009) Age, chronic non-communicable disease and choice of traditional Chinese and western medicine outpatient services in a Chinese population. BMC Health Serv Res 9:207. doi:10.1186/1472-6963-9-207
CRUK (2015) Types of treatment for lung cancer. http://www.cancerresearchuk.org/about-cancer/type/lung-cancer/treatment/which-treatment-for-lung-cancer#nonsmall. Accessed March 2015
Dai G, Tong Y, Chen X, Ren Z, Yang F (2015) In vitro anticancer activity of myricanone in human lung adenocarcinoma A549 cells. Chemotherapy 60:81–87. doi:10.1159/000371738
Gao J, Morgan WA, Sanchez-Medina A, Corcoran O (2011) The ethanol extract of Scutellaria baicalensis and the active compounds induce cell cycle arrest and apoptosis including upregulation of p53 and Bax in human lung cancer cells. Toxicol Appl Pharmacol 254:221–228. doi:10.1016/j.taap.2011.03.016
HAHK (2012) Cancer registry. http://www3.ha.org.hk/cancereg/c_stat.asp. Accessed March 2015
HPA (2011) Standardized mortality rates of cancer. https://cris.hpa.gov.tw/pagepub/Home.aspx?itemNo=cr.q.20 Accessed March 2015
Kang JT, Lee CF, Chen CF, Chou P (1994) Factors related to the choice of clinic between Chinese traditional medicine and Western medicine. J Formos Med Assoc 93(Suppl 1):S49–S55
Kao SJ et al (2012) Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression. Toxicol Appl Pharmacol 261:105–115. doi:10.1016/j.taap.2012.03.020
Konkimalla VB, Efferth T (2008) Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol 116:207–210. doi:10.1016/j.jep.2007.12.009
Li SG, Chen HY, Ou-Yang CS, Wang XX, Yang ZJ, Tong Y, Cho WC (2013) The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 8:e57604. doi:10.1371/journal.pone.0057604
Liao YH, Lin CC, Li TC, Lin JG (2012) Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan. BMC Complement Altern Med 12:146. doi:10.1186/1472-6882-12-146
Ling CQ, Wang LN, Wang Y, Zhang YH, Yin ZF, Wang M, Ling C (2014a) The roles of traditional Chinese medicine in gene therapy. J Integr Med 12:67–75. doi:10.1016/s2095-4964(14)60019-4
Ling CQ, Yue XQ, Ling C (2014b) Three advantages of using traditional Chinese medicine to prevent and treat tumor. J Integr Med 12:331–335. doi:10.1016/s2095-4964(14)60038-8
Ma WH, Duan KN, Feng M, She B, Chen Y, Zhang RM (2009) Aidi injection as an adjunct therapy for non-small cell lung cancer: a systematic review. Zhong Xi Yi Jie He Xue Bao 7:315–324. doi:10.3736/jcim20090404
Wang BR et al (2014) Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims. Patient Prefer Adherence 8:671–682. doi:10.2147/ppa.s61280
WHO (2012) Cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/online.aspx. Accessed March 2015
Xu ZY et al (2011) Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol 137:1117–1122. doi:10.1007/s00432-011-0975-3
Acknowledgements
This study was supported primarily by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW 106-TDU-B-212-113004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study was approved by the Institutional Review Board of the Public Health, Social and Behavioral Science Committee Research Ethics Committee, China Medical University (CMU-REC-101-012).
Informed consent
Informed consent of the study participants was not required because the dataset used in this study consists of de-identified secondary data released for research purposes.
Rights and permissions
About this article
Cite this article
Liao, YH., Li, CI., Lin, CC. et al. Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J Cancer Res Clin Oncol 143, 2425–2435 (2017). https://doi.org/10.1007/s00432-017-2491-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-017-2491-6